Summarized by Masters of Longevity from Longevity Technology.
A clinical trial write-up describing an experimental antibody therapy for COPD and what readers can expect to learn about its early clinical profile and next steps.
Key Takeaways
- In an 80-patient randomized double-blind trial, the antibody reduced annualized moderate-to-severe exacerbations by 24% at 600mg and 81% at 900mg.
- Severe exacerbations fell 47% at 600mg and 100% at 900mg versus placebo in the studied cohort.
- Mabwell has completed enrollment for a Phase IIb study and plans Phase III around late 2026, plus an FDA-cleared US Phase IIa IND.
